BP-GMAX-CD1: Phase I/IIa started

Bellicum began an open-label, dose-escalation, U.S. Phase I/IIa trial in 24 patients to evaluate 6 doses of intradermal BP-GMAX-CD1 given weekly or every other week in combination with activating agen...